Gaxos.ai (NASDAQ:GXAI – Get Free Report) and Castle Biosciences (NASDAQ:CSTL – Get Free Report) are both small-cap healthcare companies, but which is the better business? Analyst RecommendationsThis is a summary of current ratings and target prices for Gaxos.ai and Castle Biosciences, as provided by MarketBeat. Given Castle Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Castle Biosciences is more favorable than Gaxos.ai. Comparatively, Castle Biosciences has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. This table compares Gaxos.ai and Castle Biosciences’ net margins, return on equity and return on assets.